Chronic myelogenous leukemia: a review.

Cortes, J E; Talpaz, M; Kantarjian, H

Cortes, J E; Talpaz, M; Kantarjian, H.

Affiliation

Cortes JE; Department of Hematology, M.D. Anderson Cancer Center, Houston, Texas, 77030, USA.

Am J Med ; 100(5): 555-70, 1996 May.

Article in En | MEDLINE | ID: mdl-8644769

Subject(s)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Adult; Antimetabolites, Antineoplastic/therapeutic use; Antineoplastic Agents, Alkylating/administration & dosage; Antineoplastic Agents, Alkylating/therapeutic use; Antineoplastic Agents, Phytogenic/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Bone Marrow Transplantation; Busulfan/administration & dosage; Busulfan/therapeutic use; Cytarabine/therapeutic use; Drug Therapy, Combination; Harringtonines/therapeutic use; Homoharringtonine; Humans; Hydroxyurea/administration & dosage; Hydroxyurea/therapeutic use; Immunosuppressive Agents/administration & dosage; Immunosuppressive Agents/therapeutic use; Interferon-alpha/therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy; Middle Aged; Prognosis; Time Factors

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive Type of study: Prognostic_studies / Systematic_reviews Limits: Adult / Humans / Middle aged Language: En Journal: Am J Med Year: 1996 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links